Not available
Quote | HUTCHMED (China) Limited (NASDAQ:HCM)
Last: | $18.41 |
---|---|
Change Percent: | -2.25% |
Open: | $18.66 |
Close: | $18.41 |
High: | $18.73 |
Low: | $18.1 |
Volume: | 57,768 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | HUTCHMED (China) Limited (NASDAQ:HCM)
2024-04-07 06:30:00 ET Summary ProfoundBio, a Seattle ADC company with an R&D facility in Suzhou, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, from San Franciscoȁ...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the ...
Message Board Posts | HUTCHMED (China) Limited (NASDAQ:HCM)
Subject | By | Source | When |
---|---|---|---|
The now last up | MWM | investorshub | 05/10/2023 3:35:25 PM |
$HCM Time for this to show some returns | MWM | investorshub | 05/08/2023 7:41:07 PM |
$HCM MomentumIts gaining | crowin | investorshub | 05/08/2023 7:12:07 AM |
short squeeze | MWM | investorshub | 05/08/2023 1:11:22 AM |
$HCM The trading last up | MWM | investorshub | 05/07/2023 6:33:31 AM |
News, Short Squeeze, Breakout and More Instantly...
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; ...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the ...
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibitor — ...